keyword
MENU ▼
Read by QxMD icon Read
search

Saxagliptin

keyword
https://www.readbyqxmd.com/read/28039605/pharmacokinetic-characteristics-and-clinical-efficacy-of-an-sglt2-inhibitor-plus-dpp-4-inhibitor-combination-therapy-in-type-2-diabetes
#1
REVIEW
André J Scheen
Type 2 diabetes (T2D) generally requires a combination of several pharmacological approaches to control hyperglycaemia. Combining a sodium-glucose cotransporter type 2 inhibitor (SGLT2I, also known as gliflozin) and a dipeptidyl peptidase-4 inhibitor (DPP-4I, also known as gliptin) appears to be an attractive strategy because of complementary modes of action. This narrative review analyzes the pharmacokinetics and clinical efficacy of different combined therapies with an SGLT2I (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, tofogliflozin) and DPP-4I (linagliptin, saxagliptin, sitagliptin, teneligliptin)...
December 30, 2016: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/27979881/an-update-on-the-gliptins
#2
(no author information available yet)
Progressive impairment of insulin secretion in people with type 2 diabetes leads to blood glucose concentrations worsening over time, often resulting in escalation of blood glucose lowering therapy.(1) In 2015/2016, more money was spent on dipeptidyl peptidase-4 (DPP-4) inhibitors ('gliptins') than on any other class of antidiabetic drug except for insulins.(2) In 2008, we reviewed sitagliptin and vildagliptin.(3) Here, we briefly review three other DPP-4 inhibitors, saxagliptin (Onglyza-AstraZeneca), linagliptin (Trajenta-Boehringer Ingelheim) and ▼alogliptin (Vipidia-Takeda), and consider data from recent cardiovascular outcomes studies...
December 2016: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/27973207/cost-effectiveness-of-saxagliptin-versus-acarbose-as-second-line-therapy-in-type-2-diabetes-in-china
#3
S Gu, H Shao, Y Zeng, L Shi, H Dong
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27973205/review-of-economic-evaluation-of-saxagliptin-in-type2-diabetes-in-china
#4
C Zhang, C Hu, L Xu
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972165/cardiovascular-safety-of-saxagliptin-in-patients-with-type-2-diabetes-mellitus-a-systematic-review-and-meta-analysis
#5
R K Mothe, K Ganji, H Esam, N Likhar, S R Chidirala, A Sharma, P Jain, Y Sirumalla, A Dang
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27930863/lessons-from-a-cardiovascular-outcome-trial-with-liraglutide-in-type-2-diabetes
#6
Hae Jin Kim, Dae Jung Kim
Cardiovascular disease (CVD) is the leading cause of death and one of common diabetes-related complications in patients with type 2 diabetes(1) . After the US Food and Drug Administration issued guidelines for assessing the CVD risk of all new glucose-lowering agents for type 2 diabetes in 2008(2) , randomized controlled CV outcome trials with new antidiabetic drugs, such as the dipeptidyl peptidase-4 inhibitors (saxagliptin, alogliptin, and sitagliptin) and the glucagon-like peptide-1 receptor agonist (GLP-1 RA), lixisenatide, showed CV safety in high CV risk patient populations with type 2 diabtes(3) ...
December 8, 2016: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/27918671/dpp-4-inhibitor-treatment-in-chinese-type-2-diabetes-patients-a-meta-analysis
#7
Xiaoling Cai, Xueying Gao, Wenjia Yang, Yifei Chen, Lingli Zhou, Simin Zhang, Xueyao Han, Linong Ji
BACKGROUND: The aim of this meta-analysis was to assess the comprehensive clinical efficacy of dipeptidyl peptidase-IV (DPP-4) inhibitors in Chinese type 2 diabetes patients and to evaluate whether there is a different response to treatment with different kinds of DPP-4 inhibitors in those patients. METHODS: Databases were systematically searched, and qualifying clinical studies of Chinese type 2 diabetes patients were included. RESULTS: A total of 30 studies were included...
December 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27875596/cost-effectiveness-of-saxagliptin-versus-acarbose-as-second-line-therapy-in-type-2-diabetes-in-china
#8
Shuyan Gu, Yuhang Zeng, Demin Yu, Xiaoqian Hu, Hengjin Dong
OBJECTIVE: This study assessed the long-term cost-effectiveness of saxagliptin+metformin (SAXA+MET) versus acarbose+metformin (ACAR+MET) in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled on MET alone. METHODS: Systematic literature reviews were performed to identify studies directly comparing SAXA+MET versus ACAR+MET, and to obtain diabetes-related events costs which were modified by hospital surveys. A Cardiff Diabetes Model was used to estimate the long-term economic and health treatment consequences in patients with T2DM...
2016: PloS One
https://www.readbyqxmd.com/read/27849380/combined-treatment-with-saxagliptin-plus-dapagliflozin-reduces-insulin-levels-by-increased-insulin-clearance-and-improves-%C3%AE-cell-function
#9
Ella Ekholm, Lars Hansen, Eva Johnsson, Nayyar Iqbal, Björn Carlsson, Hungta Chen, Boaz Hirshberg
OBJECTIVE: To determine if reduction in serum insulin with dapagliflozin plus saxagliptin or dapagliflozin add-on to metformin contributed to increased insulin clearance and to assess the effects of these treatments on β-cell function. METHODS: Patients (A1C 8.0%-12.0%) were randomized to 24-week, double-blind treatment with saxagliptin 5 mg/d plus dapagliflozin 10 mg/d (n=179), saxagliptin 5 mg/d plus placebo (n=176), or dapagliflozin 10 mg/d plus placebo (n=179) added to metformin...
November 16, 2016: Endocrine Practice
https://www.readbyqxmd.com/read/27844335/cardiovascular-safety-of-incretin-based-therapies-in-type-2-diabetes-systematic-review-of-integrated-analyses-and-randomized-controlled-trials
#10
REVIEW
Edoardo Mannucci, Matteo Monami
INTRODUCTION: Regulatory requirements mandate that new drugs for treatment of patients with type 2 diabetes mellitus (T2DM), such as dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, are evaluated to show that they do not increase cardiovascular (CV) risk. METHODS: A systematic review was undertaken to evaluate the association between DPP-4 inhibitor and GLP-1 receptor agonist use and major adverse cardiac events (MACE)...
November 14, 2016: Advances in Therapy
https://www.readbyqxmd.com/read/27835045/cardiovascular-outcomes-of-new-medications-for-type-2-diabetes
#11
Jennifer M Trujillo, Sara A Wettergreen, Wesley A Nuffer, Samuel L Ellis, Michael T McDermott
Cardiovascular (CV) disease remains the leading cause of death in people with diabetes, highlighting the importance of using treatment options that do not increase CV risk or possibly decrease CV outcomes. Since 2008, the Food and Drug Administration has required demonstration of CV safety for all new medications developed for the glycemic management of diabetes. Seven trials have been published that have established CV safety for three DPP-4 inhibitors (alogliptin, saxagliptin, and sitagliptin), three GLP-1 receptor agonists (liraglutide, lixisenatide, and semaglutide), and one sodium-glucose cotransporter-2 inhibitor (empagliflozin)...
December 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27823868/effects-of-glimepiride-versus-saxagliptin-on-%C3%AE-cell-function-and-hypoglycemia-a-post-hoc-analysis-in-older-patients-with-type-2-diabetes-inadequately-controlled-with-metformin
#12
Shira Perl, William Cook, Cheryl Wei, Peter Ohman, Boaz Hirshberg
PURPOSE: The management of hyperglycemia is challenging in older patients with type 2 diabetes owing to excess fragility and risk for adverse outcomes should hypoglycemia episodes occur. We evaluated baseline β-cell function as a potential risk factor for the development of hypoglycemia when saxagliptin or glimepiride was added in patients aged ≥65 years whose type 2 diabetes was poorly controlled on stable metformin monotherapy. METHODS: A post hoc analysis of data from the GENERATION (Efficacy and Tolerability of Saxagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes: A Randomized, Controlled Study) trial, which enrolled 720 patients aged ≥65 years, was conducted...
December 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/27797925/effect-of-saxagliptin-on-renal-outcomes-in-the-savor-timi-53-trial
#13
Ofri Mosenzon, Gil Leibowitz, Deepak L Bhatt, Avivit Cahn, Boaz Hirshberg, Cheryl Wei, KyungAh Im, Aliza Rozenberg, Ilan Yanuv, Christina Stahre, Kausik K Ray, Nayyar Iqbal, Eugene Braunwald, Benjamin M Scirica, Itamar Raz
OBJECTIVE: Dipeptidyl peptidase 4 inhibitors may have a protective effect in diabetic nephropathy. RESEARCH DESIGN AND METHODS: We studied renal outcomes of 16,492 patients with type 2 diabetes, randomized to saxagliptin versus placebo and followed for a median of 2.1 years in the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) trial. RESULTS: At baseline, 9,696 (58...
January 2017: Diabetes Care
https://www.readbyqxmd.com/read/27787387/effects-of-saxagliptin-add-on-therapy-to-insulin-on-blood-glycemic-fluctuations-in-patients-with-type-2-diabetes-a-randomized-control-open-labeled-trial
#14
Feng-Fei Li, Lan-Lan Jiang, Reng-Na Yan, Hong-Hong Zhu, Pei-Hua Zhou, Dan-Feng Zhang, Xiao-Fei Su, Jin-Dan Wu, Lei Ye, Jian-Hua Ma
BACKGROUND: To investigate whether saxagliptin add-on therapy to continuous subcutaneous insulin infusion (CSII) further improve blood glycemic control than CSII therapy in patients with newly diagnosed type 2 diabetes (T2D). METHODS: This was a single-center, randomized, control, open-labeled trial. Newly diagnosed T2D patients were recruited between February 2014 and December 2015. Subjects were divided into saxagliptin add-on therapy to CSII group (n = 31) and CSII therapy group (n = 38)...
October 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27752788/the-place-of-dpp-4-inhibitors-in-the-treatment-algorithm-of-diabetes-type-2-a-systematic-review-of-cost-effectiveness-studies
#15
Alexandre Baptista, Inês Teixeira, Sónia Romano, António Vaz Carneiro, Julian Perelman
OBJECTIVE: To conduct a systematic review of cost-effectiveness, cost-utility, and cost-benefit studies of DPP-4 inhibitors for diabetes treatment versus other antidiabetics. METHODS: Three investigators searched the CRD York, Tufts CEA Registry, and MEDLINE databases through 2015. We reviewed all potentially relevant titles and abstracts, and screened full-text articles, according to inclusion criteria. We established a quality score for each study based on a 35-item list...
October 17, 2016: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/27734321/blood-glucagon-levels-predict-the-hemoglobin-a1c-response-to-saxagliptin-in-patients-with-type-2-diabetes-inadequately-controlled-with-metformin
#16
Hao Liu, Yun Hu, Feng-Fei Li, Bing-Li Liu, Xiao-Fei Su, Jian-Hua Ma
BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used as second-option medications when metformin fails. Variance of the glycated hemoglobin (HbA1c) response to DPP-4 inhibitions in patients with type 2 diabetes mellitus (T2DM) has been observed, but the characteristics which predict the response to DPP-4 inhibitor therapy are unclear. The aim of this study was to investigate the characteristics of α- and β-cell functions which might predict the efficacy of saxagliptin and facilitate personalization of treatment...
December 2016: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/27681000/prognostic-implications-of-biomarker-assessments-in-patients-with-type-2-diabetes-at-high-cardiovascular-risk-a-secondary-analysis-of-a-randomized-clinical-trial
#17
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, Itamar Raz, Matthew A Cavender, KyungAh Im, Ofri Mosenzon, Jacob A Udell, Boaz Hirshberg, Pia S Pollack, Ph Gabriel Steg, Petr Jarolim, David A Morrow
Importance: Cardiac biomarkers provide insights into pathophysiologic processes and offer an attractive strategy for the assessment of cardiovascular risk. Objective: To assess the incremental prognostic value of biomarkers that reflect different pathophysiologic processes in patients with type 2 diabetes. Design, Setting, and Participants: The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-Thrombolysis in Myocardial Infarction (TIMI) 53 is a randomized, double-blind, placebo-controlled clinical trial that evaluated the safety of saxagliptin vs placebo in 16 492 outpatients with type 2 diabetes with overt cardiovascular disease (CVD) or multiple risk factors...
December 1, 2016: JAMA Cardiology
https://www.readbyqxmd.com/read/27666017/cardiac-dpp-4-inhibition-by-saxagliptin-ameliorates-isoproterenol-induced-myocardial-remodeling-and-cardiac-diastolic-dysfunction-in-rats
#18
Junichi Ikeda, Naoya Kimoto, Tetsuya Kitayama, Shunji Kunori
Saxagliptin, a potent and selective DPP-4 inhibitor, is characterized by its slow dissociation from DPP-4 and its long half-life and is expected to have a potent tissue membrane-bound DPP-4-inhibitory effect in various tissues. In the present study, we examined the effects of saxagliptin on in situ cardiac DPP-4 activity. We also examined the effects of saxagliptin on isoproterenol-induced the changes in the early stage such as, myocardial remodeling and cardiac diastolic dysfunction. Male SD rats treated with isoproterenol (1 mg/kg/day via osmotic pump) received vehicle or saxagliptin (17...
September 2016: Journal of Pharmacological Sciences
https://www.readbyqxmd.com/read/27665059/drug-drug-interactions-between-immunosuppressants-and-antidiabetic-drugs-in-the-treatment-of-post-transplant-diabetes-mellitus
#19
REVIEW
Thomas Vanhove, Quinten Remijsen, Dirk Kuypers, Pieter Gillard
Post-transplant diabetes mellitus is a frequent complication of solid organ transplantation that generally requires treatment with lifestyle interventions and antidiabetic medication. A number of demonstrated and potential pharmacokinetic drug-drug interactions (DDIs) exist between commonly used immunosuppressants and antidiabetic drugs, which are comprehensively summarized in this review. Cyclosporine (CsA) itself inhibits the cytochrome P450 (CYP) 3A4 enzyme and a variety of drug transporters. As a result, it increases exposure to repaglinide and sitagliptin, will likely increase the exposure to nateglinide, glyburide, saxagliptin, vildagliptin and alogliptin, and could theoretically increase the exposure to gliquidone and several sodium-glucose transporter (SGLT)-2 inhibitors...
September 14, 2016: Transplantation Reviews
https://www.readbyqxmd.com/read/27659407/combined-analysis-of-three-large-interventional-trials-with-gliptins-indicates-increased-incidence-of-acute-pancreatitis-in-patients-with-type-2-diabetes
#20
Ivan Tkáč, Itamar Raz
OBJECTIVE: Data on the possible relationship of gliptin treatment to the incidence of acute pancreatitis have been controversial. The aim of the current study was to combine data on the incidence of acute pancreatitis from three large randomized controlled trials. RESEARCH DESIGN AND METHODS: Three trials designed to test cardiovascular safety and efficacy of add-on treatment with a gliptin were included in the analysis, as follows: SAVOR-TIMI 53 (saxagliptin), EXAMINE (alogliptin), and TECOS (sitagliptin)...
September 22, 2016: Diabetes Care
keyword
keyword
15054
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"